Patents by Inventor Carolina Salcedo Roca
Carolina Salcedo Roca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240109924Abstract: The present invention provides IP4-4,6 substituted derivatives, their methods of synthesis and their uses. In some aspects, the IP4-4,6 derivative is a compound of formula I wherein R1, R3, R7, and R11 are OPO32?, and R5 and R9 are selected from the group consisting of —O(Alkyl)nX, —O(Alkyl)yCy(Alkyl2)y-Z, —O(Alkyl)yA(Alkyl)y-Z?, and their thiophosphate analogs. Also provided are methods, pharmaceutical compositions and formulations, methods of use, articles of manufacture, and kits for the treatment of diseases and conditions such as pathological crystallization-related diseases and conditions.Type: ApplicationFiled: January 31, 2022Publication date: April 4, 2024Inventors: María del Mar PÉREZ FERRER, Miquel David FERRER REYNÉS, Mohamad Firas BASSISSI, Carolina SALCEDO ROCA, Carme SERRA COMAS, Juan Lorenzo CATENA RUIZ, Amadeu LLEBARIA SOLDEVILA, Joaquín ORTEGA CASTRO, Joan PERELLÓ BESTARD
-
Publication number: 20240066042Abstract: Use of a derivative containing C—O—P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.Type: ApplicationFiled: July 21, 2023Publication date: February 29, 2024Inventors: Joan PERELLO BESTARD, Carolina SALCEDO ROCA, Miguel David FERRER REYNES, Bernat ISERN AMENGUAL, Pieter H. JOUBERT
-
Publication number: 20230248749Abstract: The present invention relates to inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, for use in increasing tissular perfusion and/or oxygenation in a subject in need thereof, in particular peripheral arterial disease. The present invention also relates to pharmaceutical compositions comprising said inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, and their use in increasing tissular perfusion and/or oxygenation and for treating and preventing peripheral arterial disease.Type: ApplicationFiled: April 11, 2023Publication date: August 10, 2023Applicant: SANIFIT THERAPEUTICS, S.A.Inventors: Mohamad Firas BASSISSI, Carolina SALCEDO ROCA, Joan PERELLÓ BESTARD, Miquel David FERRER REYNÉS, María Del Mar PÉREZ FERRER
-
Publication number: 20220339171Abstract: The present invention relates to compounds, pharmaceutical compositions, combined preparations, and dosage regimens for treating, inhibiting the progression, and preventing cardiovascular calcification, and in particular, coronary calcification, aortic artery calcification, and aortic valve calcification comprising inositol phosphates. In a particular aspect the disclosure provides a dosage regimen for treating, inhibiting the progression, or preventing cardiovascular calcification comprising the administration of about 200 mg to about 700 mg of myo-inositol hexaphosphate per administration.Type: ApplicationFiled: March 17, 2022Publication date: October 27, 2022Applicant: SANIFIT THERAPEUTICS, S.A.Inventors: Joan PERELLÓ BESTARD, Carolina SALCEDO ROCA, Miquel David FERRER REYNÉS
-
Publication number: 20220249521Abstract: Use of a derivative containing C—O—P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.Type: ApplicationFiled: April 25, 2022Publication date: August 11, 2022Applicant: Sanifit Therapeutics S.A.Inventors: Joan PERELLO BESTARD, Carolina SALCEDO ROCA, Miguel David FERRER REYNES, Bernat ISERN AMENGUAL, Pieter H. JOUBERT
-
Publication number: 20220000889Abstract: The present invention relates to inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, for use in increasing tissular perfusion and/or oxygenation in a subject in need thereof, in particular peripheral arterial disease. The present invention also relates to pharmaceutical compositions comprising said inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, and their use in increasing tissular perfusion and/or oxygenation and for treating and preventing peripheral arterial disease.Type: ApplicationFiled: July 20, 2021Publication date: January 6, 2022Applicant: SANIFIT THERAPEUTICS, S.A.Inventors: Mohamad Firas BASSISSI, Carolina SALCEDO ROCA, Joan PERELLÓ BESTARD, Miquel David FERRER REYNÉS, María Del Mar PÉREZ FERRER
-
Publication number: 20210290642Abstract: The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.Type: ApplicationFiled: March 4, 2021Publication date: September 23, 2021Applicant: SANIFIT THERAPEUTICS S.A.Inventors: Joan PERELLO BESTARD, Carolina SALCEDO ROCA, Ana-Zeralda CANALS HAMANN
-
Patent number: 10973838Abstract: The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.Type: GrantFiled: February 14, 2020Date of Patent: April 13, 2021Assignee: SANIFIT THERAPEUTICS S.A.Inventors: Joan Perello Bestard, Carolina Salcedo Roca, Ana-Zeralda Canals Hamann
-
Publication number: 20200179422Abstract: The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.Type: ApplicationFiled: February 14, 2020Publication date: June 11, 2020Applicant: SANIFIT THERAPEUTICS S.A.Inventors: Joan PERELLO BESTARD, Carolina SALCEDO ROCA, Ana-Zeralda CANALS HAMANN
-
Publication number: 20190167702Abstract: Use of a derivative containing C—O—P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.Type: ApplicationFiled: December 4, 2018Publication date: June 6, 2019Applicant: LABORATORIS SANIFIT, S.L.Inventors: Joan PERELLO BESTARD, Carolina SALCEDO ROCA, Miguel David FERRER REYNES, Bernat ISERN AMENGUAL, Pieter H. JOUBERT
-
Patent number: 10010559Abstract: Use of a derivative containing C—O—P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.Type: GrantFiled: May 24, 2016Date of Patent: July 3, 2018Assignee: LABORATORIOS SANIFIT, S.L.Inventors: Joan Perello Bestard, Carolina Salcedo Roca, Miguel David Ferrer Reynes, Bernat Isern Amengual, Pieter H. Joubert
-
Publication number: 20170360810Abstract: Use of a derivative attaining C-O-P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.Type: ApplicationFiled: June 1, 2017Publication date: December 21, 2017Inventors: Joan PERELLO BESTARD, Carolina SALCEDO ROCA, Miguel David FERRER REYNES, Bernat ISERN AMENGUAL, Pieter H. JOUBERT
-
Publication number: 20170020903Abstract: Use of a derivative containing C-O-P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.Type: ApplicationFiled: May 24, 2016Publication date: January 26, 2017Inventors: Joan PERELLO BESTARD, Carolina SALCEDO ROCA, Miguel David FERRER REYNES, Bernat ISERN AMENGUAL, Pieter H. JOUBERT
-
Patent number: 9364490Abstract: Use of a derivative containing C—O—P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimirnetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.Type: GrantFiled: March 14, 2014Date of Patent: June 14, 2016Assignee: LABORATORIS SANIFIT, S.L.Inventors: Joan Perello Bestard, Carolina Salcedo Roca, Miguel David Ferrer Reynes, Bernat Isern Amengual, Pieter H. Joubert
-
Publication number: 20140271915Abstract: Use of a derivative containing C—O—P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimirnetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: LABORATORIS SANIFIT, S.L.Inventors: Joan PERELLO BESTARD, Carolina SALCEDO ROCA, Miguel David FERRER REYNES, Bernat ISERN AMENGUAL, Pieter H. JOUBERT
-
Publication number: 20100075984Abstract: Compounds of formula (I), and their pharmaceutically acceptable salts and solvates, wherein X represents —O—, —NH—, —S—, —NHC(?O)— or —NHC(?S)—; R1 represents —H or a hydrocarbon chain; R2 represents —H, alkoxy, amino, a hydrocarbon chain or a radical of a cycle; R3 represents —H, a hydrocarbon chain or a radical of a cycle; R4 represents —H or a hydrocarbon chain; alternatively R3 and R4 form together a cycle; R5 and R6 represent —H or halogen, and R7 represents —H, a hydrocarbon chain or heteroaryl, are useful against bacterial infections in animals, including humans.Type: ApplicationFiled: January 18, 2007Publication date: March 25, 2010Applicant: LABORATORIOS SALVAT, S.A.Inventors: José Hidalgo Rodríguez, Juan Lorenzo Catena Ruiz, Isabel Masip Masip, Maria del Carmen Serra Comas, Oscar Rey Puiggrós, Carmen Lagunas Arnal, Carolina Salcedo Roca, Dolors Balsa López
-
Publication number: 20090088438Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)s—N(R4)-B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed herein. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.Type: ApplicationFiled: June 25, 2008Publication date: April 2, 2009Applicant: LABORATORIOS SALVAT, S.A.Inventors: Carmen SERRA COMAS, Anna FERNANDEZ SERRAT, Dolors BALSA LOPEZ, Isabel MASIP MASIP, Juan Lorenzo CATENA RUIZ, Jose HIDALGO RODRIGUEZ, Carmen LAGUNAS ARNAL, Carolina SALCEDO ROCA, Andres FERNANDEZ GARCIA
-
Patent number: 7452904Abstract: Carbamate of general formula (I), wherein R1, R2, and R3 are H, OH, NO2, SH, CN, F, Cl, Br, I, COOH, CONH2, (C1-C4)-alkoxycarbonyl, (C1-C4)-alkylsulfanyl, (C1-C4)-alkylsulfinyl, (C1-C4)-alkylsulfonyl, (C1-C4)-alkoxyl optionally substituted with one or several F, and (C1-C4)-alkyl optionally substituted with one or several F or OH; R4 is cycloalkyl, phenyl, heteroaryl or a bicyclic ring system; R5 is cycloalkyl, (C5-C10)-alkyl, a substituted (C1-C10)-alkyl; and X? is a physiologically acceptable anion. Carbamate (I) is selective M3 receptor antagonists versus M2 receptor and may be used for the treatment of urinary incontinence (particularly, the one caused by overactive bladder), irritable bowel syndrome, and respiratory disorders (particularly, chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic interventions.Type: GrantFiled: December 18, 2002Date of Patent: November 18, 2008Assignee: Chiesi Farmaceutici S.p.A.Inventors: Juan Lorenzo Catena Ruiz, Carles Farrerons Gallemi, Anna Fernandez Serrat, Ignacio José Miquel Bono, Dolors Balsa Lopez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Natividad Toledo Mesa, Andrés Fernandez Garcia
-
Patent number: 7423172Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)s—N(R4)—B-J-T; and s. R3, R4, A, B, J and T have the meanings disclosed in the description. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.Type: GrantFiled: July 29, 2005Date of Patent: September 9, 2008Assignee: Laboratorios Salvat, S.A.Inventors: Carmen Serra Comas, Anna Fernández Serrat, Dolors Balsa López, Isabel Masip Masip, Juan Lorenzo Catena Ruiz, José Hidalgo Rodriguez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andrés Fernández García
-
Publication number: 20070276043Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)S—N(R4)—B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed in the description. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.Type: ApplicationFiled: July 29, 2005Publication date: November 29, 2007Inventors: Carmen Serra Comas, Anna Fernandez Serrat, Dolors Balsa Lopez, Isabel Masip Masip, Juan Lorenzo Catena Ruiz, Jose Hidalgo Rodriguez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andres Fernandez Garcia